Abstract 238P
Background
Small Cell Esophageal Carcinoma (SCEC) is an aggressive neuroendocrine carcinoma with early metastatic potential. Under traditional treatment modalities, radiotherapy, chemotherapy, and surgery have been used as the main treatment strategies for SCEC, but they all lead to poor prognosis. With the successful application of immunotherapy in various advanced cancer types, immunotherapy may be a rational choice for Extensive Stage Small Cell Esophageal Carcinoma (ES-SCEC).
Methods
107 consecutive patients with Extensive Stage Small Cell Esophageal Carcinoma (ES-SCEC) were identified from 5 cancer centers. The patients were divided into two groups including patients receiving immunotherapy or not. The clinicopathological characteristics, treatment information and survival time were collected from included patients. Progression-free survival (PFS) was defined as the time from drug initiation until disease progression or death from any cause, and overall survival (OS) was defined as the time from drug initiation until death or censored at last follow up. OS was assessed by the Kaplan-Meier method, with the log-rank test for comparison between groups.
Results
Patients undergoing immunotherapy demonstrate higher one-year (92.03% vs 68.75%, P=0.037) and two-year survival rates (58.67% vs 36.39%, P=0.014) compared to those who have not received immunotherapy. In the survival analysis, the median PFS was 10.13 months for patients receiving immunotherapy, and was 6.37 months for patients without immunotherapy (P=0.2319). And significant statistical difference was observed on OS between patients with or without immunotherapy (NA vs 20.63, P=0.2319). The median OS in the immunotherapy group was not yet available.
Conclusions
The results of this real-world cohort analysis suggest a positive impact of immunotherapy on OS in ES-SCEC. The immunotherapy is a reasonable treatment option for ES-SCEC.
Legal entity responsible for the study
The authors.
Funding
National Natural Science Foundation of China.
Disclosure
All authors have declared no conflicts of interest.